Trends in infection morbidity in a pediatric oncology ward, 1986-1995

Medical and Pediatric Oncology

Volumn 32, Issue 5, 1999, Pages 336-343

  Wehl, Goetz ^a   Allerberger, Franz ^a   Heitger, Andreas ^a   Meister, Bernhard ^a   Maurer, Katrin ^a   Fink, Franz Martin ^a,b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Antibiotic resistance; Cancer; Clostridium difficile; Immunocompromised host; Infection; Neutropenia

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CEFAMANDOLE; CEFTAZIDIME; CILASTATIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; PIPERACILLIN; POLYMYXIN B;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHEMOTHERAPY; CHILDHOOD CANCER; CLOSTRIDIUM DIFFICILE; FATALITY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; NEWBORN; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, MICROBIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HOSPITALIZATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MORBIDITY; NEOPLASMS; NEUTROPENIA; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0032969461     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199905)32:5<336::AID-MPO5>3.0.CO;2-4     Document Type: Article

References (46)

1. Bodey GP, Buckley M, Sathe YS, Freireich E. Quantitative relationship between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
2. Pizzo PA, Rubin M, Freifeld A, Walsh TJ. The child with cancer and infection. I. Empirical therapy for fever and neutropenia, and preventive strategies. J Pediatr 1991;119:676-694.
3. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
4. Gattringer C, Thaler J, Drach J, et al. GM-CSF treatment in aplasia after cytotoxic therapy. Onkologie 1989;12:16-18.
5. Fink FM, Maurer-Dengg K, Fritsch G, et al. Recombinant human Granulocyte-stimulating factor in septic neutropenic pediatric cancer patients: detection of circulating hematopoietic percursor cells correlates with rapid granulocyte recovery. Med Pediatr Oncol 1995;25:365-371.
6. Fink FM, Frischhut-Schiffer EM, Ausserer B, et al. Empirical antimicrobial therapy of infection and fever episodes in children and adolescents neutropenic caused by cytotoxic chemotherapy. Pädiatr Pädol 1989;24:33-42.
7. Mahmood S, Revesz T, Mpofu C. Febrile episodes in children with cancer in the United Arab Emirates. Pediatr Hematol Oncol 1996;13:135-142.
8. al Fawaz IM, Kambal AM, al Rabeeah AA, et al. Septicaemia in febrile neutropenic children with cancer in Saudi Arabia. J Hosp Infect 1991;18:307-312.
9. Pizzo PA, Ladisch S, Simon RM, et al. Increasing incidence of gram-positive sepsis in cancer patients. Med Pediatr Oncol 1978; 5:241-244.
10. Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 1987;97:503-508.
11. Winston DJ, Dudnick DV, Chapin M, et al. Coagulase negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med 1983;143:32-36.
12. EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive septicemias in granulocytopenic cancer patients. Eur J Cancer 1990;26:569-574.
13. Awada A, van der Auwera P, Daneau D, Klastersky J. Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 1992;15:33-48.
14. Rubin M, Hathorn JW, Marshall D, et al. Gram-positive infections and the use of vancomycin in 350 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-35.
15. Kern W, Kurrle E, Vanek E. High risk of streptococcal septicemia after high-dose cytosine arabinoside treatment for acute myelogenous leukemia. Klin Wochenschr 1987;65:773-780.
16. Jacoby GA, Medeiros AA. More extended-spectrum β-lactamases. Antimicrob Agents Chemother 1991;35:1697-1704.
17. Medeiros AA. Nosocomial outbreaks of multiresistant bacteria: extended-spectrum β-lactamases have arrived in North America. Ann Intern Med 1993;119:428-430.
18. Pizzo PA. Antibiotic prophylaxis in immunosuppressed patients with cancer. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases, 4th ed. New York: McGraw-Hill; 1983. p 153.
19. Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia: ciprofloxacin versus co-trimoxazole plus colistin, The EORTC-Gnotobiotic Project Group. Eur J Cancer 1992;28A:873-878.
20. Walsh TJ, Lee J, Lecciones J, et al. Empirical amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991;13:496-503.
21. Stein RS, Kayser J, Flexner J. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer 1982;50:2247.
22. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-672.
23. Emminger W, Lang HRM, Emminger-Schmidmeier W, et al. Amphotericin B serum levels in pediatric bone marrow recipients. Bone Marrow Transplant 1991;7:95-99.
24. Hawkins C, Armstrong D. Fungal infections in the immunocompromised host. Clin Haematol 1984;13:599-630.
25. Meunier C. New methods for delivery of antifungal agents. Rev Infect Dis 1989;11(suppl 7):1605-1612.
26. Persson U, Tenvall GR, Andersson S, et al. Cost-effectiveness analysis of treatment with liposomal amphotericin B in organ or bone marrow transplant recipients with systemic mycosis. Pharmaco Econ 1992;2:500-508.
27. Larson HE, Price AB, Honour P. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978;20:1063-1066.
28. Rampling A, Warren RE, Bevan PC. Clostridium difficile in hematological malignancies. J Clin Pathol 1985;38:445-451.
29. Morris GJ, Jarvis WR, Nunez-Moutiel OL. Clostridium difficile: colonisation and toxin production in a cohort of patients with malignant hematologic disorders. Arch Intern Med 1984;144:967-969.
30. Cudmore AM, Silva J Jr, Fehety R. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med 1982;142: 333-335.
31. Nielson H, Daugaard G, Tvede M. High prevalence of Clostridium difficile diarrhoe during intensive chemotherapy for disseminated germ cell cancer. Br J Cancer 1992;66:666-667.
32. Gerard M, Defrasne N, Daneau D, et al. Incidence and significance of Clostridium difficile in hospitalized patients. Eur J Clin Microbiol Infect Dis 1988;7:274-278.
33. Schuller I, Saha V, Lin L, et al. Investigation and management of Clostridium difficile colonisation in a paediatric oncology unit. Arch Dis Child 1995;72:219-222.
34. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993;17: 109-13.
35. Wade DS, Nava HR, Douglass HO Jr. Neutropenic enterocolitis: clinical diagnosis and treatment. Cancer 1992;69:17-23.
36. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-558.
37. Shenep JL, Hughes WT, Robertson PK, et al. Vancomycin, ticarcillin and amikacin compared with ticarcillin-clavulate and amikacin in the empirical treatment of febrile neutropenic children with cancer. N Engl J Med 1988;319:1053-1058.
38. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J 1991;10:918-923.
39. Lydaki E, Bolonaki E, Stiakaki E, et al. Efficacy of recombinant human granulocyte-macrophage colony stimulating factor in neutropenic children with malignancies. Pediatr Hematol Oncol 1995; 12:551-558.
40. Lyman GH, Lyman CH, Sandersson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Nat Cancer Inst 1993;85:488-493.
41. Vellenga E, Uyl de Groot R, de Witt HJ, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor with chemotherapy-related febrile neutropenia. J Clin Oncol 1996;14:619-627.
42. Maher DW, Lieschke GJ, Green M, et al. Filgastrim in patients with chemotherapy-induced febrile neutropenia. Ann Intern Med 1994;121:492-501.
43. Biesma B, de Vries EGE, Willemse PHB, et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating with chemotherapy-related leukopenia and fever. Eur J Cancer 1992;26:932-936.
44. Riikonen P, Saarinen UM, Mäkipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo controlled study in children. Pediatr Infect Dis J 1994;13:197-200.
45. Mayordomo FI, Rivera F, Diaz-Puent MZ, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;11: 803-808.
46. Wexler LH, Weaver-McClure L, Steinberg SM, et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelo-suppressive chemotherapy. J Clin Oncol 1996;14:901-910.